Gilead to Initiate P-I Study Evaluating Inhaled Version of Remedesivir Against COVID-19 in August 2020

 Gilead to Initiate P-I Study Evaluating Inhaled Version of Remedesivir Against COVID-19 in August 2020

Gilead to Initiate P-I Study Evaluating Inhaled Version of Remedesivir Against COVID-19 in August 2020Gilead to Initiate P-I Study Evaluating Inhaled Version of Remedesivir Against COVID-19 in August 2020

Shots:

  • Following the US FDA’s approval, Gilead will screen healthy volunteers for P-I study this week and plans to initiate the study in patients with COVID-19 in Aug’2020. The therapy could be given to patients via nebulizer, which would allow for easier dosing outside the hospital and in earlier stages of the disease
  • The inhaled formulation will explore the use of Remdesivir in the earlier stages of COVID-19. The company will conduct a trial using IV infusion in outpatient settings such as infusion centers and nursing homes while the patients with a high risk of disease progression, it could be helpful to start treatment outside the hospital
  • The company is also evaluating Remdesivir with other therapies while the company anticipates the manufacturing of the therapy by the end of 2020and many millions more by 2021

Click here to read full press release/ article | Ref: Gilead | Image: The Intercept

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post